Comparative Pharmacology
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus THYROLAR 0 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus THYROLAR 0 25.
LEVOTHYROXINE SODIUM vs THYROLAR-0.25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
Thyroid hormone (liothyronine, L-triiodothyronine or T3) binds to thyroid hormone receptors in the nucleus, altering gene transcription and protein synthesis, leading to increased metabolic rate, oxygen consumption, and thermogenesis.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
Oral, 0.25 mg (1 tablet) once daily; adjust based on TSH response.
None Documented
None Documented
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
Levothyroxine (T4): ~7 days; liothyronine (T3): ~1 day. Clinical context: Steady-state achieved in ~5 weeks for T4; T3 half-life shorter leads to more frequent dosing if used alone.
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Renal: ~40% as conjugated metabolites (glucuronides and sulfates); fecal: ~20% via bile; minor biliary elimination of parent drug (<5%). Total renal clearance of iodine: ~30%.
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone